1. Membrane Transporter/Ion Channel
    Neuronal Signaling
  2. GlyT


Glycine transporters (GlyTs) belong to a large family of Na+/Cl--dependent transporter proteins that includes transporters for monoamines [5-hydroxytryptamine (serotonin), noradrenaline and dopamine] and γ-aminobutyric acid. GlyT-mediated glycine uptake is energetically coupled with the transmembrane sodium gradient maintained by the Na+/K+-ATPase.

GlyT1 is essential for regulating glycine concentrations at synaptic receptors.

GlyT2 is uniquely designed for neurotransmitter recycling at inhibitory glycinergic synapses, and loss of GlyT2 function generates a severely hyperexcited state.

GlyT Related Products (13):

Cat. No. Product Name Effect Purity
  • HY-10809
    Bitopertin Inhibitor 99.68%
    Bitopertin is a potent, noncompetitive glycine reuptake inhibitor, inhibits glycine uptake at human GlyT1 with a concentration exhibiting IC50 of 25 nM.
  • HY-101037
    Sarcosine Inhibitor
    Sarcosine (N-Methylglycine; Sarcosin), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor an N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].
  • HY-10716A
    PF-03463275 Inhibitor 99.57%
    PF-03463275 is a centrally penetrant, orally available, selective, and competitive GlyT1 (glycine transporter-1) reversible inhibitor, with a Ki of 11.6 nM. PF-03463275 has the potential for Schizophrenia research[1][2].
  • HY-100416A
    LY2365109 hydrochloride Inhibitor 99.32%
    LY2365109 hydrochloride is a potent and selective GlyT1 inhibitor, with an IC50 of 15.8 nM for glycine uptake in cells over-expressing hGlyT1a[1][2].
  • HY-130466
    Stearoyl-L-carnitine chloride Inhibitor
    Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2. Stearoyl-L-carnitine chloride inhibits glycine responses by 16.8% at concentrations up 3 μM[1][2].
  • HY-10809A
    Bitopertin (R enantiomer) Inhibitor
    Bitopertin R enantiomer (RG1678 R enantiomer; RO4917838 R enantiomer) is the R-enantiomer of Bitopertin. Bitopertin is a potent, noncompetitive glycine reuptake inhibitor, inhibits glycine uptake at human GlyT1 with a concentration exhibiting IC50 of 25 nM.
  • HY-112432
    GlyT1 Inhibitor 1 Inhibitor
    GlyT1 Inhibitor 1 is a potent and selective GlyT1 inhibitor with an IC50 of 38 nM for rGlyT1[1]. Antipsychotic activity[1].
  • HY-107526
    NFPS Inhibitor
    NFPS is a selective, non-competitive glycine transporter-1 (GlyT1) inhibitor with IC50s of 2.8 nM and 9.8 nM for hGlyT1 and rGlyT1, respectively[1]. NFPS exerts neuroprotection via glyR alpha1 subunit in the rat model of transient focal cerebral ischaemia and reperfusion[2].
  • HY-111029
    ALX-1393 Inhibitor
    ALX-1393, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model[1].
  • HY-110176
    ASP2535 Inhibitor 99.70%
    ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease[1].
  • HY-19887
    Tilapertin Inhibitor
    Tilapertin is an oral inhibitor of glycine transporter type-1 (GlyT1).
  • HY-109067
    Opiranserin Antagonist
    Opiranserin, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. Opiranserin shows antagonistic activity on rP2X3 (IC50=0.87 μM). Opiranserin is development as an injectable agent for the treatment of postoperative pain[1][2][3].
  • HY-101334
    MPDC Inhibitor
    MPDC is a potent and competitive inhibitor of the Na+-dependent high-affinity glutamate transporter in forebrain synaptosomes[1].